Sorrento: Multiple Progresses Have Been Made

By Grant Zeng, CFA NASDAQ:SRNE Sorrento Initiates Pivotal Trial of Cynviloq On March 31, 2014, Sorrento Therapeutics (NASDAQ:SRNE) announced that the first patient has been dosed in the pivotal clini...